VAR2 Pharma Phase 0 Trial
Oncology
Phase 0Active
Key Facts
About TRACER Europe
TRACER Europe is a pioneering imaging CRO that leverages Phase 0 microdosing and molecular imaging to de-risk and accelerate drug development for biopharma sponsors. Its core service involves labeling a sponsor's drug candidate (antibody, small molecule, peptide, etc.) to visualize and quantify its behavior in human patients at a very early stage, enabling critical go/no-go decisions before costly traditional trials. Founded in 2018, the private company operates in a high-growth niche, helping clients reduce development costs and timelines by providing human proof-of-concept data faster than conventional pathways.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |